Cargando…

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Annunziata, Mario, Bonifacio, Massimiliano, Breccia, Massimo, Castagnetti, Fausto, Gozzini, Antonella, Iurlo, Alessandra, Pregno, Patrizia, Stagno, Fabio, Specchia, Giorgina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280484/ https://www.ncbi.nlm.nih.gov/pubmed/32582549 http://dx.doi.org/10.3389/fonc.2020.00883

Ejemplares similares

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey
por: Breccia, Massimo, et al.
Publicado: (2023)

Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
por: Latagliata, Roberto, et al.
Publicado: (2016)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome
por: Houshmand, Mohammad, et al.
Publicado: (2021)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2021)

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
por: Gugliotta, Gabriele, et al.
Publicado: (2017)

Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
por: Bocchia, Monica, et al.
Publicado: (2018)

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
por: Fava, Carmen, et al.
Publicado: (2019)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study
por: Caocci, Giovanni, et al.
Publicado: (2020)

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
por: Loscocco, Federica, et al.
Publicado: (2021)

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
por: Specchia, Giorgina, et al.
Publicado: (2021)

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome
por: Iurlo, Alessandra, et al.
Publicado: (2016)

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
por: Castagnetti, Fausto, et al.
Publicado: (2021)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Management of Chronic Myeloid Leukemia in Advanced Phase
por: Bonifacio, Massimiliano, et al.
Publicado: (2019)

Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study
por: Gugliotta, Gabriele, et al.
Publicado: (2022)

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy
por: Borghi, Lidia, et al.
Publicado: (2021)

RARG Gene Dysregulation in Acute Myeloid Leukemia
por: Conserva, Maria Rosa, et al.
Publicado: (2019)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
por: Dragani, Matteo, et al.
Publicado: (2020)

Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
por: Houshmand, Mohammad, et al.
Publicado: (2022)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
por: Breccia, Massimo, et al.
Publicado: (2023)

Flow Cytometry Assessment of CD26(+) Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
por: Raspadori, Donatella, et al.
Publicado: (2019)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
por: Iurlo, A., et al.
Publicado: (2023)

Single-Cell Sequencing: Ariadne’s Thread in the Maze of Acute Myeloid Leukemia
por: Redavid, Immacolata, et al.
Publicado: (2022)

Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
por: Tarantini, Francesco, et al.
Publicado: (2021)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Treatment Recommendations for Chronic Myeloid Leukemia
por: Baccarani, Michele, et al.
Publicado: (2014)

SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia
por: Albano, Francesco, et al.
Publicado: (2012)

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
por: Efficace, F, et al.
Publicado: (2012)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
por: Malagola, Michele, et al.
Publicado: (2021)

Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
por: Ito, Kyoko, et al.
Publicado: (2021)

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients
por: Ricciardi, Maria Rosaria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p1gavnonp7m26rqs82g1f1a4k0